Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 16/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 12/20 | 0.45 |
| ▸ | PDE4C | Q08493 | 11/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 11/20 | 0.45 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.41 |
| ▸ | TPH1 | P17752 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7241642 | 0.79 | PDE4A (0.50) | PDE4APDE4BPDE4CPDE4DSSTR5 | |
| SCHEMBL29623586 | 0.78 | PDE4A (0.52) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL196243 | 0.78 | PDE4A (0.52) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7676524 | 0.78 | PDE4B (0.45) | PDE4APDE4BPDE4CPDE4DSSTR5 | |
| Hydrochloric Acid SCHEMBL30543740 | 0.77 | PDE4A (0.51) | PDE4APDE4BPDE4CPDE4D | |
| Hydrochloric Acid SCHEMBL154624 | 0.77 | PDE4A (0.51) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6418035 | 0.74 | PDE4A (0.42) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL8978342 | 0.74 | PDE4B (0.44) | PDE4APDE4BPDE4CPDE4DSSTR5 | |
| Hydrochloric Acid SCHEMBL7032971 | 0.73 | PDE4B (0.43) | PDE4APDE4BPDE4CPDE4DSSTR5 | |
| SCHEMBL7380391 | 0.73 | PDE4A (0.50) | PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050112069-A1 | Pharmaceutical composition of a pde4 or pde 3/4 inhibitor and histamine receptor antagonist | NYCOMED GMBH (DE) | 2005-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050112069-A1 | Pharmaceutical composition of a pde4 or pde 3/4 inhibitor and histamine receptor antagonist | HRH4, PDE4A, PDE4B | PDE4A 2/4885PDE4B 3/4885PDE4C 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.